Jubilant Generics Limited
Records under this name other than the patents Jubilant Generics Limited holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 2 patents it holds.
Back to Jubilant Generics Limited
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,233,955 | Process For The Preparation Of Azilsartan Medoxomil Formerly held In force · High confidence | In force | High confidence | |
| US 9,346,760 | Process for the Preparation of (S)-(+)- or (R)-(-)-10-Hydroxy Dihydrodibenz[b,f]azepines by Enantioselective Reduction of 10,11-Dihydro-10-OXO-5H-DIBENZ[B,F]AZEPINES and Polymorphs Thereof Formerly held In force · High confidence | In force | High confidence | |
| US 10,252,986 | Process for the Preparation of Exametazime Formerly held In force · High confidence | In force | High confidence | |
| US 9,932,336 | Process for the Preparation of Apixaban and Intermediates Thereof Formerly held In force · High confidence | In force | High confidence | |
| US 10,836,781 | Process for the preparation of tetrofosmin or acid salt thereof Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 11,857,647 | Pharmaceutical composition comprising tetrofosmin and pharmaceutically acceptable salts thereof Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 11,471,543 | Pharmaceutical compositions of sulfur colloid and processes thereof Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 11,331,324 | Modified release suspension of eslicarbazepine Lapsed on the fee record Ended May 17, 2026 · From the USPTO record | Lapsed on the fee record | Ended May 17, 2026 | From the USPTO record |
| US 11,327,065 | Preparation of angiotensin receptor blockers or pharmaceutically acceptable salts thereof Lapsed on the fee record Ended May 10, 2026 · High confidence | Lapsed on the fee record | Ended May 10, 2026 | High confidence |
| US 11,318,145 | Eslicarbazepine suspension Lapsed on the fee record Ended May 3, 2026 · From the USPTO record | Lapsed on the fee record | Ended May 3, 2026 | From the USPTO record |